The Swiss pharmaceutical giant Roche is set to pay $450 million for a Danish biotech company that develops drugs that silence microRNAs (something considered key to tackling certain diseases).
Roche is targeting the Danish biotech firm Santaris Pharma, according to The Wall Street Journal. Santaris Pharma A/S is a biopharmaceutical company founded in 2003 in Copenhagen. Santaris Pharma A/S has become a leading clinical-stage biopharmaceutical company that develops RNA-targeted medicines. Santaris works on developing drugs for a wide range of diseases using microRNA and mRNA. Their research focuses on infectious disease and metabolic disorders.